Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Alector

This page shows the latest Alector news and features for those working in and with pharma, biotech and healthcare.

GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul

GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul

Since then, the pharma company announced its first deal following the reveal of its ten-year strategy – a $2.2bn monoclonal antibody (mAb) deal with US biotech Alector in the neurodegenerative

Latest news

  • GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

    GlaxoSmithKline has announced a new $2.2bn deal with US biotech company Alector to co-develop monoclonal antibodies for a number of neurodegenerative diseases. ... disease. Under the terms of the deal, GSK will pay Alector $700m upfront, with further

  • Biogen and Eisai pull plug on Alzheimer’s drug Biogen and Eisai pull plug on Alzheimer’s drug

    One example is US biotech Alector, whose lead candidate AL002 targets a triggering receptor expressed on myeloid cells 2 (TREM2) and is based on a view that the disease is caused

  • Alector kicks off next wave of biotech IPOs Alector kicks off next wave of biotech IPOs

    Alector is pioneering immuno-neurology, a novel therapeutic that will treat a range of degenerative brain disorders by restoring healthy immune function to the brain. ... Hot on Alector’s heels is Stealth BioTherapeutics, which is aiming to raise $81

  • J&J and Bayer unveil new bioincubators J&J and Bayer unveil new bioincubators

    Places in J&J's bioincubators have already yielded funding and licensing deals for the likes of Alector, Bell Biosystems and Araxes Pharma.

  • J&J adds Manchester to partnering network J&J adds Manchester to partnering network

    Alector is targeting key components of the pathological pathways that underlie Alzheimer's using monoclonal antibody technology via its strategic alliance with antibody discovery specialist Adimab. ... This agreement provides Alector with a lot of

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Angus Grant, CEO of the Dementia Discovery Fund, said: “I am delighted that Alector, the first of DDF’s investments, has reached this significant milestone. ... Alector’s progress serves as a great illustration of how the DDF’s investment choices

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...

Quick links